Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240044/S002

Globe Catheter (601-01000)

Kardium, Inc. · Decision date Feb 18, 2026

FDA DECISIONP240044/S002

What did the FDA approve?

FDA records P240044/S002 as a supplement to PMA P240044, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 18, 2026.

FDA approval order statement

request approval for an update to the Globe Catheter instructions for use (IFU) to provide simplified catheter preparation and air management procedures
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Feb 18, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P240044/S002
Regulatory pathway
PMA supplement
Applicant
Kardium, Inc.
Product code
QZI
Decision code
APPR
Decision date
Feb 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Applicant
Kardium, Inc.
Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P240044. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240044 · Original PMA

    Globe Pulsed Field System

  2. P240044/S002 received

    Application receipt date recorded by FDA.

  3. P240044/S003 · Related supplement

    Globe Pulsed Field System

  4. P240044/S004 · Related supplement

    Globe Catheter; Globe Pulsed Field System

  5. P240044/S002 · FDA decision

    Real-Time Process

  6. P240044/S005 · Related supplement

    Globe Catheter; Globe Pulsed Field System

  7. P240044/S001 · Related supplement

    Globe Catheter and Globe Pulsed Field System

  8. P240044/S006 · Related supplement

    Globe Catheter Laminated Ribs

  9. P240044/S008 · Related supplement

    Globe Pulsed Field System; Globe Catheter

  10. P240044/S007 · Related supplement

    Globe Catheter and Globe Pulsed Field System

Timeline entries are records held by MedtechLedger for P240044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240044

Product / regulatory recordCompanyPathwayDecision dateSource
Kardium, Inc.PMA approvalAug 27, 2025FDA
Kardium, Inc.PMA supplementJan 6, 2026FDA
Kardium, Inc.PMA supplementJan 9, 2026FDA
Kardium, Inc.PMA supplementJun 12, 2026FDA
Kardium, Inc.PMA supplementJun 23, 2026FDA
Kardium, Inc.PMA supplementAug 20, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Kardium, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
8518 Glenlyon Pkwy., Unit 155, Burnaby, V5J OB6

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records